Physician profile
Waleed Mohammad
NPI 1487150181
$21,250.59
in general payments reported to CMS, 2019-2025
12 companies · $13K in 2025
The $13K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.46 · 2020: $759 · 2021: $2,418 · 2022: $1,914 · 2023: $1,060 · 2024: $2,072 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Travel and Lodging: $4,473 · Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Travel and Lodging | $4,473.41 |
| Food and Beverage | $1,658.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $11,144.31 | 2022-2025 | |
| Pinnacle, INC | $4,461.29 | 2020-2022 | |
| Stryker Corporation | $2,979.59 | 2022-2024 | Pro, Gamma, Ortholoc 3di |
| Synthes Gmbh | $2,029.77 | 2025 | |
| Depuy Synthes Sales INC. | $198.38 | 2024-2025 | Na, Tfn-Advance |
| Elite Orthopedics, LLC | $132.20 | 2025 | |
| Heron Therapeutics, INC. | $120.83 | 2024 | Zynrelef |
| Kerecis Limited | $101.80 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbott Laboratories | $27.46 | 2019 | |
| Integra Lifesciences Corporation | $21.61 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $19.89 | 2024 | Pico 14, Pico 7 |
| Cardiva Medical, INC. | $13.46 | 2023 | Cardiva Vascade 6/7f Vcs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waleed Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.